메뉴 건너뛰기




Volumn 60, Issue 9, 2017, Pages 1620-1629

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Author keywords

Cardiovascular disease; Meta analysis; Metformin; Review; Systematic review

Indexed keywords

METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

EID: 85026729294     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4337-9     Document Type: Review
Times cited : (318)

References (40)
  • 1
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
    • (1998) Lancet , vol.352 , pp. 837-853
  • 2
    • 82755165018 scopus 로고    scopus 로고
    • Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
    • PID: 22115901
    • Hemmingsen B, Schroll JB, Wetterslev J et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
    • (2011) BMJ , vol.343 , pp. d6898
    • Hemmingsen, B.1    Schroll, J.B.2    Wetterslev, J.3
  • 3
    • 79960959816 scopus 로고    scopus 로고
    • Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
    • PID: 21791495
    • Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169
    • (2011) BMJ , vol.343 , pp. d4169
    • Boussageon, R.1    Bejan-Angoulvant, T.2    Saadatian-Elahi3
  • 4
    • 85016474227 scopus 로고    scopus 로고
    • Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
    • PID: 28365411
    • Zoungas S, Arima H, Gerstein HC et al (2017) Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5:431–437
    • (2017) Lancet Diabetes Endocrinol , vol.5 , pp. 431-437
    • Zoungas, S.1    Arima, H.2    Gerstein, H.C.3
  • 5
  • 6
    • 49649098865 scopus 로고    scopus 로고
    • Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies
    • PID: 18458139
    • Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31:1672–1678
    • (2008) Diabetes Care , vol.31 , pp. 1672-1678
    • Rao, A.D.1    Kuhadiya, N.2    Reynolds, K.3    Fonseca, V.A.4
  • 7
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • COI: 1:CAS:528:DC%2BD2sXms1SisrY%3D, PID: 17517853
    • Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.1    Wolski, K.2
  • 8
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    • COI: 1:CAS:528:DC%2BD2MXhtVOlu7fO, PID: 16214598
    • Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 9
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • COI: 1:CAS:528:DC%2BC2MXhtlKrtbnN, PID: 26052984
    • Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 10
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • COI: 1:CAS:528:DC%2BC28XhvF2ks77O, PID: 27295427
    • Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 11
    • 0015401059 scopus 로고
    • A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
    • COI: 1:STN:280:DyaE383ms1Gnsw%3D%3D, PID: 5055722
    • Seltzer HS (1972) A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976–979
    • (1972) Diabetes , vol.21 , pp. 976-979
    • Seltzer, H.S.1
  • 12
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
    • (1998) Lancet , vol.352 , pp. 854-865
  • 13
    • 85026812421 scopus 로고    scopus 로고
    • Metformin: historical overview
    • Bailey CJ (2017) Metformin: historical overview. Diabetologia DOI: 10.1007/s00125-017-4318-z
    • (2017) Diabetologia
    • Bailey, C.J.1
  • 14
    • 84860167144 scopus 로고    scopus 로고
    • Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
    • PID: 22509138
    • Boussageon R, Supper I, Bejan-Angoulvant T et al (2012) Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9:e1001204
    • (2012) PLoS Med , vol.9
    • Boussageon, R.1    Supper, I.2    Bejan-Angoulvant, T.3
  • 15
    • 78851470539 scopus 로고    scopus 로고
    • Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
    • COI: 1:CAS:528:DC%2BC3MXjtFSgtr4%3D, PID: 21205121
    • Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13:221–228
    • (2011) Diabetes Obes Metab , vol.13 , pp. 221-228
    • Lamanna, C.1    Monami, M.2    Marchionni, N.3    Mannucci, E.4
  • 16
    • 84901768284 scopus 로고    scopus 로고
    • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
    • COI: 1:CAS:528:DC%2BC2cXpslCrsb8%3D, PID: 24910232
    • Holman RR, Sourij H, Califf RM (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383:2008–2017
    • (2014) Lancet , vol.383 , pp. 2008-2017
    • Holman, R.R.1    Sourij, H.2    Califf, R.M.3
  • 17
    • 69449100622 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • PID: 19622551
    • Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
    • (2009) BMJ , vol.339 , pp. b2535
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 19
    • 0036895990 scopus 로고    scopus 로고
    • Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes
    • PID: 12453903
    • Hällsten K, Virtanen KA, Lonnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479–3485
    • (2002) Diabetes , vol.51 , pp. 3479-3485
    • Hällsten, K.1    Virtanen, K.A.2    Lonnqvist, F.3
  • 20
    • 0035663674 scopus 로고    scopus 로고
    • Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
    • COI: 1:CAS:528:DC%2BD38XnvVSisg%3D%3D, PID: 11903415
    • Hermann LS, Kalen J, Katzman P et al (2001) Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 3:428–434
    • (2001) Diabetes Obes Metab , vol.3 , pp. 428-434
    • Hermann, L.S.1    Kalen, J.2    Katzman, P.3
  • 21
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • COI: 1:CAS:528:DC%2BD1cXht1Wgt7nK, PID: 18784090
    • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
    • (2008) N Engl J Med , vol.359 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3    Matthews, D.R.4    Neil, H.A.5
  • 22
    • 63849328978 scopus 로고    scopus 로고
    • Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus
    • COI: 1:CAS:528:DC%2BD1MXksVOntrY%3D, PID: 19307526
    • Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616–625
    • (2009) Arch Intern Med , vol.169 , pp. 616-625
    • Kooy, A.1    de Jager, J.2    Lehert, P.3
  • 23
    • 79951694164 scopus 로고    scopus 로고
    • Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study
    • PID: 20929990
    • Gram J, Henriksen JE, Grodum E et al (2011) Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 34:27–33
    • (2011) Diabetes Care , vol.34 , pp. 27-33
    • Gram, J.1    Henriksen, J.E.2    Grodum, E.3
  • 24
    • 0035374524 scopus 로고    scopus 로고
    • The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes
    • COI: 1:CAS:528:DC%2BD3MXks1agurw%3D, PID: 11375358
    • Chiasson JL, Naditch L (2001) The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 24:989–994
    • (2001) Diabetes Care , vol.24 , pp. 989-994
    • Chiasson, J.L.1    Naditch, L.2
  • 25
    • 0029099086 scopus 로고
    • Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
    • COI: 1:CAS:528:DyaK2MXpsVanurY%3D, PID: 7623902
    • DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541–549
    • (1995) N Engl J Med , vol.333 , pp. 541-549
    • DeFronzo, R.A.1    Goodman, A.M.2
  • 26
    • 0033754777 scopus 로고    scopus 로고
    • Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
    • COI: 1:CAS:528:DC%2BD3cXot1ahs7s%3D, PID: 11092289
    • Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665
    • (2000) Diabetes Care , vol.23 , pp. 1660-1665
    • Horton, E.S.1    Clinkingbeard, C.2    Gatlin, M.3    Foley, J.4    Mallows, S.5    Shen, S.6
  • 27
    • 0036791054 scopus 로고    scopus 로고
    • Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications
    • COI: 1:CAS:528:DC%2BD38XnvVKmu74%3D, PID: 12384131
    • Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M (2002) Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 13:428–433
    • (2002) Eur J Intern Med , vol.13 , pp. 428-433
    • Rachmani, R.1    Slavachevski, I.2    Levi, Z.3    Zadok, B.4    Kedar, Y.5    Ravid, M.6
  • 28
    • 84959478814 scopus 로고    scopus 로고
    • Metformin as firstline treatment for type 2 diabetes: are we sure?
    • PID: 26747716
    • Boussageon RF, Gueyffier F, Cornu C (2016) Metformin as firstline treatment for type 2 diabetes: are we sure? BMJ 352:h6748
    • (2016) BMJ , vol.352 , pp. h6748
    • Boussageon, R.F.1    Gueyffier, F.2    Cornu, C.3
  • 29
    • 54949090768 scopus 로고    scopus 로고
    • Cardiovascular outcomes in trials of oral diabetes medications: a systematic review
    • Selvin E, Bolen S, Yeh HC et al (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168:2070–2080
    • (2008) Arch Intern Med , vol.168 , pp. 2070-2080
    • Selvin, E.1    Bolen, S.2    Yeh, H.C.3
  • 30
    • 14644390253 scopus 로고    scopus 로고
    • Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study
    • COI: 1:CAS:528:DC%2BD2MXivVaisrw%3D, PID: 15735184
    • Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV (2005) Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 28:539–543
    • (2005) Diabetes Care , vol.28 , pp. 539-543
    • Cryer, D.R.1    Nicholas, S.P.2    Henry, D.H.3    Mills, D.J.4    Stadel, B.V.5
  • 31
    • 84920025605 scopus 로고    scopus 로고
    • Metformin in patients with type 2 diabetes and kidney disease: a systematic review
    • Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675
    • (2014) JAMA , vol.312 , pp. 2668-2675
    • Inzucchi, S.E.1    Lipska, K.J.2    Mayo, H.3    Bailey, C.J.4    McGuire, D.K.5
  • 32
    • 84907296915 scopus 로고    scopus 로고
    • Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders
    • Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 79:867–885
    • (2014) Cancer Prev Res , vol.79 , pp. 867-885
    • Gandini, S.1    Puntoni, M.2    Heckman-Stoddard, B.M.3
  • 33
    • 84866138849 scopus 로고    scopus 로고
    • Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
    • COI: 1:CAS:528:DC%2BC38XhtlWlsrjP, PID: 22875195
    • Stevens RJ, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593–2603
    • (2012) Diabetologia , vol.55 , pp. 2593-2603
    • Stevens, R.J.1    Fernandez-Esteban, I.2    Mataix, A.3    Ausejo, M.4    Roque, M.5    Moher, D.6
  • 34
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • COI: 1:CAS:528:DC%2BC28XntVSkurs%3D, PID: 26378978
    • Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 35
    • 85014781627 scopus 로고    scopus 로고
    • Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    • COI: 1:CAS:528:DC%2BC2sXktFyju7c%3D, PID: 28283684
    • Florez JC (2017) Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia 60:800–807
    • (2017) Diabetologia , vol.60 , pp. 800-807
    • Florez, J.C.1
  • 36
    • 0037034257 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    • COI: 1:CAS:528:DC%2BD38XhtVWqurc%3D, PID: 11832527
    • Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
    • (2002) N Engl J Med , vol.346 , pp. 393-403
    • Knowler, W.C.1    Barrett-Connor, E.2    Fowler, S.E.3
  • 37
    • 31844452061 scopus 로고    scopus 로고
    • The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
    • Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297
    • (2006) Diabetologia , vol.49 , pp. 289-297
    • Ramachandran, A.1    Snehalatha, C.2    Mary, S.3
  • 38
    • 85026778634 scopus 로고    scopus 로고
    • Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study
    • Aroda VR, Knowler WC, Crandal JP et al (2017) Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia DOI: 10.1007/s00125-017-4361-9
    • (2017) Diabetologia
    • Aroda, V.R.1    Knowler, W.C.2    Crandal, J.P.3
  • 39
    • 4644336398 scopus 로고    scopus 로고
    • Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk
    • COI: 1:CAS:528:DC%2BD2cXos1Cjtrg%3D, PID: 15381514
    • Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413–420
    • (2004) Ann Intern Med , vol.141 , pp. 413-420
    • Khaw, K.T.1    Wareham, N.2    Bingham, S.3    Luben, R.4    Welch, A.5    Day, N.6
  • 40
    • 84859977229 scopus 로고    scopus 로고
    • Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses
    • PID: 22517929
    • Hemmingsen B, Christensen LL, Wetterslev J (2012) Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 344:e1771
    • (2012) BMJ , vol.344
    • Hemmingsen, B.1    Christensen, L.L.2    Wetterslev, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.